DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291

DYRK1A is considered a potential cancer therapeutic target, but the role of DYRK1A in NSCLC oncogenesis and treatment requires further investigation. In our study, high DYRK1A expression was observed in tumour samples from patients with lung cancer compared with normal lung tissues, and the high lev...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cell Mol Med
Main Authors: Li, Yang‐ling, Ding, Ke, Hu, Xiu, Wu, Lin‐wen, Zhou, Dong‐mei, Rao, Ming‐jun, Lin, Neng‐ming, Zhang, Chong
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6815810/
https://ncbi.nlm.nih.gov/pubmed/31454149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14609
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados